Advanced search×

Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.

J Neurosci 30(3):1166-75 (2010) PMID 20089925

We report that rapamycin, an allosteric inhibitor of certain but not all actions of the key cellular kinase mammalian target of rapamycin (mTOR), protects neurons from death in both cellular and animal toxin models of Parkinson's disease (PD). This protective action appears to be attributable to blocked translation of RTP801/REDD1/Ddit4, a protein that is induced in cell and animal models of PD and in affected neurons of PD patients and that causes neuron death by leading to dephosphorylation of the survival kinase Akt. In support of this mechanism, in PD models, rapamycin spares phosphorylation of Akt at a site critical for maintenance of its survival-promoting activity. The capacity of rapamycin to provide neuroprotection in PD models appears to arise from its selective suppression of some but not all actions of mTOR, as indicated by the contrasting finding that Torin1, a full catalytic mTOR inhibitor, is not protective and induces Akt dephosphorylation and neuron death.

DOI: 10.1523/JNEUROSCI.3944-09.2010
Version: za2963e q8za7 q8zb8 q8zc0 q8zdd q8zee q8zf7 q8zg2

Similar articles you may find interesting…

  1. Predicting environmental chemical factors associated with disease-related gene expression data.

    Audio, Transactions of the IRE Professional Gro... (2010) PMID 20459635

    We have developed a scalable and statistical method to identify possible environmental associations with disease using publicly available data and have validated some of the associations in the literature....
  2. Detecting disease associated modules and prioritizing active genes based on high throughput data

    BMC Bioinformatics 11(1):26 (2010) PMID 20070902

    By applying the proposed method to two cancer related problems, i.e. breast cancer and prostate cancer, we successfully identified active modules or dysfunctional pathways related to these two types of cancers with literature confirmed evidences. We show that this network-based method is highly effi...
  3. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.

    Australas J Dermatol 51(1):36-8 (2010) PMID 20148840

    Our case report underlines the possible wide range of clinical signs in Fabry disease patients, sometimes complicated by missing typical lesions (e.g. angiokeratomas). In oligosymptomatic Fabry disease cases, genetic analysis is recommended....